Flexibility and speed for oligo hybridization microfluidic assays are achievable without sacrificing sensitivity or robustness.

The development of oligonucleotide-based therapeutics is a rapidly growing effort, with regulatory approvals and opportunities for the treatment of orphan and genetic diseases fueling expansion. Methods for sensitive and efficient quantitation are critical to the success of these programs. In this webinar, we present optimization of microfluidic, automated ligand-binding hybridization assays for the detection of the anti-sense oligonucleotide (ASO) drug casimersen using variations that provide flexibility in automation and assay conditions to meet the needs of the therapeutic molecule. The simplicity, speed and sensitivity of Gyrolab assays show promise for accelerating data turnaround in preclinical and clinical PK/TK studies of oligonucleotide therapeutics.

Webinar topics:

• Adaptation of hybridization oligo quantitation assays onto a microfluidic automated platform
• Online or offline assay incubations and advantages of each
• Assay performance for fully- and semi-automated microfluidic oligo assays
• Accelerating assay run times for microfluidic assays

John Chappell has approximately 25 years of experience in the Contract Research industry supporting both preclinical and clinical drug development, specializing in supporting biological compounds from an analytical perspective including pharmacokinetic, immunogenicity and biomarker analysis. 

If you have problems viewing the webinar, please contact maritha.lundin@gyrosproteintech.com